We hold the technology to make individualized oncology therapies a reality
TCXpress™ and NEOXpress™, working together, can match T-cell receptors (TCRs) with their targets, and within the context of certain patients, discover TCRs against tumor-specific antigens (neoantigens).
These technologies hold the power to unlock the potential of T-cell therapy for the treatment of cancer.
A proprietary high-throughput and efficient TCR search and capture platform, TCXpress™ is capable of processing thousands of single T cells directly into functionally expressed TCRs within a matter of days, thereby creating extensive libraries without the need for lengthy predictive sequencing.
A proprietary patient-specific neoantigen discovery platform, NEOXpress™ screens tumor-resident TCRs for reactivity to identified neoantigens. In this bottom-up approach, together with T-cell reporter libraries created from TCXpress™, NEOXpress™ provides the opportunity to rapidly screen and test the function of thousands of TCRs to find those specific to key neoantigens in a multiplexed way.